When the Seattle Times featured a story about Seattle Genetics and the biotechnology company’s CEO Clay Siegall, the media outlet explained how the Bothell-based company’s stock rose over 50 percent in 2016 thanks to the effectiveness of their signature product, the cancer drug Adcetris. Adcetris is an antibody-drug conjugate (ADC) that targets the protein molecules on the outside of Hodgkin lymphoma cancer cells and then, using Seattle Genetic’s linker, Adcetris burrows inside the cancer cell and releases its toxin, sparing more healthy cells than traditional chemotherapy. Under Siegall’s leadership, Seattle Genetics is making a name for itself in Seattle’s flourishing biotech industry.
Also featured in a George Washington University School of Medicine and Health Sciences publication, Siegall’s alma mater, he is praised for his dedication to research in targeting cancer cells. Fondly remembering his time studying for his Ph.D in Genetics, Siegall said that Ajit Kumar, Ph.D, his Ph.D. mentor, guided his early career in research, including his postdoctoral fellowship at the National Institutes of Health, where he wrote numerous papers on targeted cancer therapies. After viewing his research focus, Bristol-Myers Squibb offered Siegall an ideal position in Seattle that allowed him to work on cancer therapies. However, Siegall eventually left Bristol-Myers Squibb to co-found Seattle Genetics.
Currently, Seattle Genetics has one successful drug on the market in over 60 countries and a dozen additional cancer drugs in development. Social Synergy Web reports that Seattle Genetics will hire 100 more employees in the United States and 20 more for their Switzerland office. Busy as ever, Siegall maintains a seat on the board of three biotechnology companies in addition to serving as Seattle Genetics’ Chairman of the Board of Directors as well.